Tags

Type your tag names separated by a space and hit enter

Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia.
Int J Antimicrob Agents. 2014 Aug; 44(2):160-2.IJ

Abstract

Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.

Authors+Show Affiliations

Microbiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia.Microbiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia.Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Global and Tropical Health Division, Menzies School of Health Research, Darwin, NT 0810, Australia.Microbiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia. Electronic address: rob.baird@nt.gov.au.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24924662

Citation

Crowe, Amy, et al. "Current Antimicrobial Susceptibility of First-episode Melioidosis Burkholderia Pseudomallei Isolates From the Northern Territory, Australia." International Journal of Antimicrobial Agents, vol. 44, no. 2, 2014, pp. 160-2.
Crowe A, McMahon N, Currie BJ, et al. Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. Int J Antimicrob Agents. 2014;44(2):160-2.
Crowe, A., McMahon, N., Currie, B. J., & Baird, R. W. (2014). Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. International Journal of Antimicrobial Agents, 44(2), 160-2. https://doi.org/10.1016/j.ijantimicag.2014.04.012
Crowe A, et al. Current Antimicrobial Susceptibility of First-episode Melioidosis Burkholderia Pseudomallei Isolates From the Northern Territory, Australia. Int J Antimicrob Agents. 2014;44(2):160-2. PubMed PMID: 24924662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. AU - Crowe,Amy, AU - McMahon,Nicole, AU - Currie,Bart J, AU - Baird,Robert W, Y1 - 2014/05/28/ PY - 2014/04/05/received PY - 2014/04/07/accepted PY - 2014/6/14/entrez PY - 2014/6/14/pubmed PY - 2015/3/31/medline KW - Antimicrobial susceptibility KW - Burkholderia pseudomallei KW - Melioidosis SP - 160 EP - 2 JF - International journal of antimicrobial agents JO - Int. J. Antimicrob. Agents VL - 44 IS - 2 N2 - Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/24924662/Current_antimicrobial_susceptibility_of_first_episode_melioidosis_Burkholderia_pseudomallei_isolates_from_the_Northern_Territory_Australia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(14)00141-1 DB - PRIME DP - Unbound Medicine ER -